| human | Q5 |
| P496 | ORCID iD | 0000-0003-0517-0554 |
| P735 | given name | Kenneth | Q2492643 |
| Kenneth | Q2492643 | ||
| P106 | occupation | researcher | Q1650915 |
| Q96641970 | A Phase 1, Open Label- Assessment of a Dengue Virus-1 Live Virus Human Challenge - (DENV-1-LVHC) Strain |
| Q45408057 | A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. |
| Q36026204 | A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico |
| Q36523070 | A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults |
| Q35272502 | An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques |
| Q40504189 | An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model |
| Q84957571 | Cell-Mediated Immunity Generated in Response to a Purified Inactivated Vaccine for Dengue Virus Type 1 |
| Q92093930 | Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions |
| Q40414894 | Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies |
| Q38963303 | Dengue Virus Exposures Among Deployed U.S. Military Personnel |
| Q44438134 | Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine |
| Q47315490 | Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. |
| Q40265040 | Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines |
| Q35625036 | Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines |
| Q99613937 | Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase I Randomized Clinical Trial |
| Q91517216 | Immunological Assays used to Support Efficacy of Zika Virus Vaccines |
| Q40318917 | Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate |
| Q26314710 | Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children |
| Q40541524 | Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys. |
| Q27489793 | Passage of Dengue Virus Type 4 Vaccine Candidates in Fetal Rhesus Lung Cells Selects Heparin-Sensitive Variants That Result in Loss of Infectivity and Immunogenicity in Rhesus Macaques |
| Q33773563 | Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States |
| Q39955421 | Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults |
| Q54260853 | Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico |
| Q40536052 | Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine |
| Q89519312 | Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor |
| Q45323630 | Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials |
| Q38990645 | Production and testing of dengue virus strains suitable for human infection studies |
| Q35645556 | Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. |
| Q40479018 | Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination. |
| Q26248722 | Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys |
| Q34542032 | Rapid development of a DNA vaccine for Zika virus |
| Q89988839 | Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I Study |
| Q36026210 | Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial |
| Q35131443 | Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine in Flavivirus-Naive Infants |
| Q93334736 | Safety and Immunogenicity of an AS03B-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study |
| Q96954885 | Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial |
| Q33841045 | Safety and immunogenicity of a rederived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial |
| Q40424733 | Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. |
| Q40541513 | Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates |
| Q25165129 | Vaccine protection against Zika virus from Brazil |
Search more.